<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tumor necrosis factor-alpha inhibitors: Bacterial, viral, and fungal infections</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tumor necrosis factor-alpha inhibitors: Bacterial, viral, and fungal infections</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Tumor necrosis factor-alpha inhibitors: Bacterial, viral, and fungal infections</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kevin L Winthrop, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Emily A Blumberg, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheila Bond, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Inhibitors of tumor necrosis factor (TNF)-alpha represent important treatment advances for a number of inflammatory conditions, including rheumatoid arthritis, the seronegative spondyloarthropathies, psoriasis, and inflammatory bowel disease. TNF-alpha inhibitors offer a targeted strategy that contrasts with the nonspecific immunosuppressive agents traditionally used to treat most forms of systemic inflammation.</p><p>However, multiple adverse effects of TNF-alpha inhibition have been identified. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Infections</p><p class="bulletIndent1"><span class="glyph">●</span>Malignancies such as nonmelanoma skin cancers</p><p class="bulletIndent1"><span class="glyph">●</span>Injection site reactions</p><p class="bulletIndent1"><span class="glyph">●</span>Infusion reactions</p><p class="bulletIndent1"><span class="glyph">●</span>Induction of autoimmunity (eg, uveitis, psoriasis)</p><p class="bulletIndent1"><span class="glyph">●</span>Demyelinating disease</p><p class="bulletIndent1"><span class="glyph">●</span>Heart failure</p><p></p><p>Infections associated with bacterial, viral, and fungal organisms will be reviewed here. Other major complications of TNF-alpha therapy such as tuberculosis and nontuberculous mycobacterial infections, malignancy, the induction of autoimmunity, demyelinating disease, and heart failure are discussed separately. (See  <a class="medical medical_review" href="/d/html/1411.html" rel="external">"Risk of mycobacterial infection associated with biologic agents and JAK inhibitors"</a> and  <a class="medical medical_review" href="/d/html/7975.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Risk of malignancy"</a> and  <a class="medical medical_review" href="/d/html/7974.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases"</a> and  <a class="medical medical_review" href="/d/html/7970.html" rel="external">"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects"</a>.)</p><p>The biology of TNF-alpha and some of its effects on the immune system are reviewed elsewhere. (See  <a class="medical medical_review" href="/d/html/7970.html" rel="external">"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">TNF-ALPHA INHIBITORS</span><span class="headingEndMark"> — </span>Several inhibitors of TNF-alpha have been approved for the treatment of a variety of inflammatory illnesses (eg, rheumatoid arthritis, Crohn disease) by the US Food and Drug Administration. These medications are:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">Infliximab</a> – A chimeric (mouse/human) anti-TNF-alpha monoclonal antibody</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">Adalimumab</a> – A fully human monoclonal anti-TNF-alpha antibody</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">Etanercept</a> – A soluble TNF-alpha receptor fusion protein</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8644" href="/d/drug information/8644.html" rel="external">Certolizumab pegol</a> – A pegylated Fab fragment of a humanized monoclonal antibody</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9086" href="/d/drug information/9086.html" rel="external">Golimumab</a> – A human monoclonal anti-TNF-alpha antibody</p><p></p><p>These agents are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/7966.html" rel="external">"Overview of biologic agents in the rheumatic diseases"</a>.)</p><p class="headingAnchor" id="H2825005606"><span class="h1">TNF-ALPHA AND HOST DEFENSES</span><span class="headingEndMark"> — </span>TNF-alpha is synthesized initially by activated macrophages and T cells as a transmembrane precursor protein. The cytoplasmic tail of this protein is then cleaved to release soluble TNF-alpha. TNF-alpha is important for macrophage activation, phagosome activation, differentiation of monocytes into macrophages, recruitment of neutrophils and macrophages, and granuloma formation and function [<a href="#rid1">1</a>].</p><p>Animal experiments have demonstrated the importance of TNF-alpha in protection against several pathogens, including <em>Mycobacterium tuberculosis</em>, <em>Mycobacterium avium</em>, <em>Mycobacterium bovis</em>, Bacillus Calmette-Guérin (BCG), <em>Aspergillus fumigatus</em>, <em>Histoplasma capsulatum</em>, <em>Coccidioides</em> species, <em>Toxoplasma gondii</em>, <em>Cryptococcus neoformans</em>, <em>Candida albicans</em>, and multiple viral pathogens<em> </em>[<a href="#rid2">2-6</a>]. These organisms are not killed readily by host defense mechanisms but rather are sequestered within granulomas, which are comprised of a central core of macrophages, multinucleated giant cells, and necrotic debris surrounded by macrophages and lymphocytes [<a href="#rid7">7</a>]. TNF-alpha is required for the orderly recruitment of these cells and for continued maintenance and function of the granuloma [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H11650657"><span class="h1">SCREENING FOR INFECTIONS</span><span class="headingEndMark"> — </span>A variety of recommendations have been issued regarding screening for certain infections; prior to receiving a TNF-alpha inhibitor, patients should be screened for tuberculosis, hepatitis B, and hepatitis C [<a href="#rid9">9-12</a>]. Screening for these infections is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1411.html" rel="external">"Risk of mycobacterial infection associated with biologic agents and JAK inhibitors", section on 'Screening'</a> and  <a class="medical medical_review" href="/d/html/3680.html" rel="external">"Hepatitis B virus: Screening and diagnosis in adults"</a> and  <a class="medical medical_review" href="/d/html/89950.html" rel="external">"Screening and diagnosis of chronic hepatitis C virus infection"</a>.)</p><p>It is also important to obtain a history of possible recent (ie, in the last two years) infection with endemic fungi, as discussed below. (See <a class="local">'Histoplasmosis'</a> below and <a class="local">'Coccidioidomycosis'</a> below and <a class="local">'Cryptococcus'</a> below.)</p><p class="headingAnchor" id="H11650707"><span class="h1">CONTRAINDICATIONS</span><span class="headingEndMark"> — </span>The American College of Rheumatology recommends that TNF-alpha inhibitors <strong>not</strong> be administered when any of the following infections are present [<a href="#rid12">12,13</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Active bacterial infections or bacterial infections requiring antibiotic therapy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Active tuberculosis (TB) or untreated latent TB (see  <a class="medical medical_review" href="/d/html/1411.html" rel="external">"Risk of mycobacterial infection associated with biologic agents and JAK inhibitors"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Active herpes zoster infection</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Active invasive fungal infections (eg, coccidioidomycosis, invasive aspergillosis)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nonhealed infected skin ulcers</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acute infection with hepatitis B virus (HBV) or hepatitis C virus (HCV), untreated chronic HBV infection, or chronic HBV or HCV infection with significant liver injury, defined as Child-Pugh classes B or C (<a class="calc calc_professional" href="/d/html/15639.html" rel="external">calculator 1</a>)</p><p></p><p>We agree with these recommendations. If a TNF-alpha inhibitor is started in a patient with chronic HBV infection (ie, positive HbSag), antiviral therapy should be used concomitantly. (See <a class="local">'Hepatitis B'</a> below.)</p><p>Decisions about the appropriate timing for initiating a TNF-alpha inhibitor following resolution of the infections described above should be made on a case-by-case basis. For some infections (eg, coccidioidomycosis, pulmonary nontuberculous mycobacteria), resolution can be difficult to identify or document, and the decision regarding anti-TNF therapy resumption or initiation (potentially with concomitant antimicrobial therapy) should be made in conjunction with an infectious diseases specialist.</p><p class="headingAnchor" id="H3"><span class="h1">ASSESSING THE RISK OF SERIOUS INFECTION</span><span class="headingEndMark"> — </span>Data from randomized trials and long-term open-label extension studies of biologic therapies have generally (but not always) suggested some increase in infectious risks associated with these compounds. While these studies have the benefit of being randomized with regard to drug exposure at the start of the study, they are often small, include relatively healthy patients (ie, lacking comorbidities), are underpowered to evaluate uncommon events, and often involve patients using concomitant immunosuppressants (eg, <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>) that also can increase infectious risk. In addition, patients with rheumatoid arthritis and certain other inflammatory diseases have higher rates of pneumonia, skin and soft tissue infections, and other serious infections due to the underlying disease itself [<a href="#rid14">14</a>]. The majority of these infections are thought to be bacterial, although community-acquired viruses (eg, influenza) likely also play an important role.</p><p>A 2011 network meta-analysis that included 50,010 patients from 163 randomized trials and 46 long-term open-label extension studies (some of which involved biologic agents other than TNF-alpha inhibitors) showed an elevated risk of serious infections (ie, infections requiring hospitalization) for each TNF-alpha inhibitor, although the risk was only statistically significant for certolizumab (odds ratio [OR] 3.51, 95% CI 1.59-7.79) [<a href="#rid15">15</a>]. A 2015 meta-analysis that included 106 randomized trials of patients with rheumatoid arthritis who received biologic drugs found that standard-dose biologic drugs (OR 1.31, 95% CI 1.09-1.58) and high-dose biologic drugs (OR 1.90, 95% CI 1.50-2.39) were associated with an increased risk of serious infections compared with traditional disease-modifying antirheumatic drugs (DMARDs), but low-dose biologic drugs were not [<a href="#rid16">16</a>]. The risk was lower in patients who were methotrexate-naive compared with those who had previously received a traditional DMARD or a TNF-alpha inhibitor.</p><p>In general, observational studies have the benefit of evaluating risk in "real-world" populations and often have great statistical power. Given the lack of randomization, however, confounding can skew results, although several elegant studies have used propensity scores and other methods in an attempt to control for this. Many registry and population-based studies have documented "real-world" incidence rates of infection. Most, but not all, of these studies have suggested an increased risk in infection requiring hospitalization in patients receiving a TNF-alpha inhibitor, particularly during the first 6 to 12 months after drug initiation. Incidence rates from a selection of these population-based studies range from 2.9 to 8.2 infections requiring hospitalization per 100 patient-years of exposure to a TNF-alpha inhibitor [<a href="#rid17">17</a>]. Several studies suggest a higher risk of infection requiring hospitalization with <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> than with <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a> or <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a>, although it is unclear whether this is due to the drug itself or differences in concomitant immunosuppressive use or other factors [<a href="#rid18">18-20</a>]. A 2018 study from the British registry suggested similar risks between all of the TNF-alpha inhibitors and that risks could be higher with <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a>, a biologic agent that inhibits the interleukin 6 receptor [<a href="#rid21">21</a>].</p><p>Perhaps the most robust analysis with regard to controlling for differences between exposed populations before and after drug initiation comes from the German biologic registry. After controlling for concomitant <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> use in time-varying fashion as well as for various comorbidities, a statistically significant increased risk (incidence rate ratio 1.8, 95% CI 1.2-2.7) for infection requiring hospitalization was found to be associated with TNF-alpha inhibitor (<a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a>, <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a>, and <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> were studied) use [<a href="#rid22">22</a>]. The investigators developed a risk calculator and showed that the majority of infection risk is related to patient factors (ie, comorbidities and age) and concomitant use of prednisone.</p><p>Other population-based studies in the United States have had some variability in risk estimates. In a large retrospective population-based study using Medicare, health plan, and health maintenance organization data in patients with rheumatoid arthritis (RA), inflammatory bowel disease, psoriatic arthritis, or ankylosing spondylitis, no increase in the risk of hospitalization for infection was observed in patients initiating treatment with a TNF-alpha inhibitor compared with nonbiologic agents [<a href="#rid23">23</a>]. Among patients with RA, <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> was associated with an increased risk of serious infections compared with <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a> (adjusted hazard ratio [aHR] 1.26, 95% CI 1.07-1.47) and <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a> (aHR 1.23, 95% CI 1.02-1.48). An accompanying editorial pointed out that possible reasons for the lack of difference in the risk of hospitalization include multiple potential confounders in both treatment groups as well as the possibility that the infection rate in the comparator group may have been higher than in prior studies [<a href="#rid24">24</a>].</p><p>The US Food and Drug Administration has stated that patients receiving a TNF-alpha inhibitor who are greater than 65 years of age or who are taking concomitant immunosuppressants may be at even greater risk of infection [<a href="#rid25">25</a>]. The absolute risks are higher for older adults, although the relative risk between TNF-alpha inhibitors and nonbiologic DMARDs in this group remains similar [<a href="#rid22">22,26</a>]. Some comorbidities can also elevate the risk of serious infections substantially. As an example, in the United States population-based analysis described above, the crude incidence of infections requiring hospitalization for patients taking a TNF-alpha inhibitor without chronic obstructive pulmonary disease (COPD) was 7.2 per 100 patient-years (95% CI 6.5-8.1), whereas it was more than twice as high (15.0 per 100 patient-years, 95% CI 11.8-18.9) in those with COPD [<a href="#rid23">23</a>].</p><p>Most studies of infections in patients receiving TNF-alpha inhibitors have been conducted in adults. In a systematic review of studies that focused on children and adolescents receiving a TNF-alpha inhibitor for juvenile idiopathic arthritis or inflammatory bowel disease, the most frequently reported infections were upper respiratory tract infections and other mild infections [<a href="#rid27">27</a>]. Severe bacterial and fungal infections also occurred. Few patients developed tuberculosis, likely due at least in part to effective screening.</p><p class="headingAnchor" id="H2282600762"><span class="h1">TIMING OF INFECTION RISK</span><span class="headingEndMark"> — </span>Some data indicate that the risk of infection associated with TNF-alpha inhibitor use is highest in the period shortly after the initiation of therapy. In an analysis of the British Society for Rheumatology Biologics Register [<a href="#rid28">28</a>], the adjusted incidence ratio for infection was not elevated for patients receiving TNF-alpha inhibitors compared with those on disease-modifying antirheumatic drugs alone (ratio 1.22, 95% CI 0.88-1.69). However, when the analysis was limited to the first 90 days of follow-up after the initiation of a new therapy, the adjusted incidence rate ratio was 4.6 (95% CI 1.8-11.9) among patients treated with TNF-alpha inhibitors.</p><p>Increased risk of tuberculosis in the period immediately following the institution of TNF-alpha inhibition has also been reported. (See  <a class="medical medical_review" href="/d/html/1411.html" rel="external">"Risk of mycobacterial infection associated with biologic agents and JAK inhibitors"</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">MYCOBACTERIAL INFECTIONS</span><span class="headingEndMark"> — </span>All TNF-alpha inhibitors increase the risk of tuberculosis (TB), and all patients should be evaluated for TB, both by history and screening assays, prior to starting therapy. (See  <a class="medical medical_review" href="/d/html/1411.html" rel="external">"Risk of mycobacterial infection associated with biologic agents and JAK inhibitors", section on 'Quantifying risk for TB'</a>.)</p><p>The risk of nontuberculous mycobacterial (NTM) infections is also increased with TNF-alpha inhibitor therapy [<a href="#rid29">29,30</a>]. In the United States, pulmonary and extrapulmonary NTM infections are several-fold more common than TB. The approach to diagnosis and management of NTM infections for patients receiving TNF-alpha inhibitor therapy is discussed separately. (See  <a class="medical medical_review" href="/d/html/1411.html" rel="external">"Risk of mycobacterial infection associated with biologic agents and JAK inhibitors", section on 'Nontuberculous mycobacterial disease'</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">BACTERIAL INFECTIONS</span></p><p class="headingAnchor" id="H6"><span class="h2">Risk of bacterial infections</span><span class="headingEndMark"> — </span>The majority of infections requiring hospitalization described in the clinical trial and population-based studies above have been evaluated or reported without regard to specific site of infection or pathogen and have been presumed to be due to common bacterial pathogens (see <a class="local">'Assessing the risk of serious infection'</a> above). However, some studies have reported either site-specific infections or specific bacterial pathogens, as discussed below.</p><p class="headingAnchor" id="H1210178637"><span class="h2">Septic arthritis</span><span class="headingEndMark"> — </span>The British Society for Rheumatology Biologics Register, a prospective observational study of patients with rheumatoid arthritis, compared the risk of septic arthritis in 11,881 patients who received a TNF-alpha inhibitor and 3673 patients who received nonbiologic disease-modifying antirheumatic drugs (DMARDs) [<a href="#rid31">31</a>]. One hundred seventy-nine patients who received a TNF-alpha inhibitor had at least one episode of septic arthritis compared with 20 patients who received DMARDs. The adjusted hazard ratio for septic arthritis in patients who received a TNF-alpha inhibitor was 2.3 (95% CI 1.2-4.4). The risk was highest in the early months following initiation of TNF-alpha inhibitor therapy and did not differ based upon which TNF-alpha inhibitor was used.</p><p><em>Staphylococcus aureus</em> was the most common cause of septic arthritis in both cohorts, occurring in 57 percent of patients who received a TNF-alpha inhibitor and 43 percent of patients who received DMARDs. In the patients who received a TNF-alpha inhibitor, several cases were caused by organisms that rarely cause septic arthritis, including five cases caused by intracellular pathogens (three cases caused by <em>Salmonella</em> spp and two cases caused by <em>Listeria </em>spp) and four cases caused by <em>Pseudomonas aeruginosa</em>. (See  <a class="medical medical_review" href="/d/html/7666.html" rel="external">"Septic arthritis in adults"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Listeriosis</span><span class="headingEndMark"> — </span><em>Listeria monocytogenes</em> is a gram-positive intracellular bacterium that is associated most often with meningoencephalitis and/or septicemia. The disease is linked to the ingestion of contaminated dairy and meat products. (See  <a class="medical medical_review" href="/d/html/1277.html" rel="external">"Clinical manifestations and diagnosis of Listeria monocytogenes infection"</a>.)</p><p>Listeriosis has been described in patients receiving TNF-alpha inhibitors [<a href="#rid25">25,30,32-34</a>], and, in 2011, the US Food and Drug Administration (FDA) added a boxed warning about the risk of listeriosis for the entire class of TNF-alpha inhibitors [<a href="#rid25">25</a>]. In a report on granulomatous infectious diseases from the FDA Adverse Events Reporting System from 1998 to 2002, there were 38 cases of <em>Listeria</em> infection: 36 with <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> and 2 with <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a> (15.5 versus 1.8 per 100,000 patients, a difference that was highly significant) [<a href="#rid30">30</a>]. A search of the medical literature in 2011 identified 26 published cases of listeriosis in patients who had received a TNF-alpha inhibitor, including seven deaths [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/d/html/1280.html" rel="external">"Epidemiology and pathogenesis of Listeria monocytogenes infection"</a>.)</p><p>The acquisition of <em>Listeria</em> through the ingestion of contaminated foods emphasizes the importance of educating patients regarding food preparation and safety. Preventive measures to minimize the risk of foodborne <em>Listeria</em> infection are discussed separately. (See  <a class="medical medical_review" href="/d/html/1303.html" rel="external">"Treatment and prevention of Listeria monocytogenes infection", section on 'Prevention of foodborne infection'</a>.)</p><p class="headingAnchor" id="H1446752307"><span class="h2">Legionella pneumonia</span><span class="headingEndMark"> — </span>In 2011, the FDA added a boxed warning about the risk of <em>Legionella</em> infection for the entire class of TNF-alpha inhibitors [<a href="#rid25">25</a>]. This warning was issued because an increased risk of <em>Legionella</em> infection was detected among patients who had received a TNF-alpha inhibitor. Between 1999 and 2010, 80 cases of <em>Legionella</em> pneumonia, including four deaths, were reported to the FDA's Adverse Events Reporting System in patients receiving a TNF-alpha inhibitor.<br/><br/>A population-based study conducted in France suggested that <em>Legionella</em> pneumonia risk with TNF-alpha inhibitors is elevated as compared with the general population and that higher risk exists with <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a> and <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> than with <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a> [<a href="#rid35">35</a>].</p><p><em>Legionella</em> infection is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/7035.html" rel="external">"Clinical manifestations and diagnosis of <i>Legionella </i>infection"</a> and  <a class="medical medical_review" href="/d/html/7025.html" rel="external">"Treatment and prevention of <i>Legionella</i> infection"</a> and  <a class="medical medical_review" href="/d/html/7029.html" rel="external">"Microbiology, epidemiology, and pathogenesis of <i>Legionella </i>infection", section on 'Host risk factors'</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Other important pathogens</span><span class="headingEndMark"> — </span>Other serious bacterial infections have been reported across the class of TNF-alpha inhibitors, including but not limited to nocardiosis, actinomycosis, and salmonellosis [<a href="#rid30">30,36</a>].</p><p class="headingAnchor" id="H9"><span class="h1">VIRAL INFECTIONS</span><span class="headingEndMark"> — </span>There are few data related to the impact of TNF-alpha inhibitor use on patients with viral infections. The effects of TNF-alpha inhibition on the course of viral infections may vary according to the specific type of infection. As an example, inhibition of TNF-alpha appears to delay the clearance of hepatitis B but may attenuate hepatic injury with hepatitis C [<a href="#rid37">37-39</a>]. For severe acute respiratory syndrome coronavirus 2, observational data suggest patients using TNF-alpha inhibitors at the time of infection might have a lower or neutral risk of severe coronavirus disease 2019 outcomes [<a href="#rid40">40,41</a>]. </p><p class="headingAnchor" id="H10"><span class="h2">Hepatitis B</span><span class="headingEndMark"> — </span>The potential exists for reactivation of certain viral infections by TNF-alpha inhibitor therapy either directly due to lack of TNF-alpha or indirectly via effects on T cell activation and interferon (IFN) production. This appears most relevant in the case of hepatitis B virus (HBV), an intracellular infection that is controlled by cytokine and cellular mechanisms [<a href="#rid37">37,38,42</a>]. There are a number of reports of patients with HBV infections that reactivated during treatment with TNF-alpha inhibitors or other biologic agents [<a href="#rid43">43-48</a>].</p><p>The American College of Rheumatology recommends that patients with active HBV infection who are receiving or have received effective antiviral therapy should be treated for rheumatoid arthritis (RA) according to recommendations for those without hepatitis B infection (ie, they should receive a TNF-alpha inhibitor if indicated) [<a href="#rid12">12</a>]. In contrast, they recommend that TNF-alpha inhibitors be avoided in patients with untreated chronic HBV infection or with chronic HBV infection with significant liver injury, defined as Child-Pugh classes B or C (<a class="calc calc_professional" href="/d/html/15639.html" rel="external">calculator 1</a>) [<a href="#rid13">13</a>]. We agree with these recommendations. (See <a class="local">'Contraindications'</a> above.)</p><p>In patients with untreated HBV infection who do not have Child-Pugh class B or C liver injury, a TNF-alpha inhibitor can be given, although some patients require antiviral therapy to prevent HBV reactivation. We use the following approach [<a href="#rid49">49-51</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In HBsAg-positive patients (ie, patients with chronic HBV) starting a TNF-alpha inhibitor, we recommend starting an antiviral agent (eg, tenofovir or <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a>) prior to initiating the TNF-alpha inhibitor.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who are HBsAg negative but HBcAb positive (resolved HBV), we monitor for viral reactivation during TNF-alpha inhibitor therapy, particularly in those lacking evidence of immunity (HBsAb negative). In such patients, we check HBV DNA and transaminase levels before starting therapy and every three months thereafter. Some experts monitor HBV DNA and transaminases at more frequent intervals (ie, every one to two months) [<a href="#rid52">52</a>]. We initiate antiviral therapy if reactivation occurs. This issue is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy", section on 'Categorizing level of risk'</a> and  <a class="medical medical_review" href="/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy", section on 'Summary and recommendations'</a>.)</p><p></p><p class="headingAnchor" id="H11"><span class="h2">Hepatitis C</span><span class="headingEndMark"> — </span>All patients should be screened for hepatitis C infection before starting TNF-alpha inhibitor therapy. Patients with chronic hepatitis C virus (HCV) infection should be treated given the wide availability of safe and effective antiviral therapy. (See  <a class="medical medical_review" href="/d/html/3673.html" rel="external">"Overview of the management of chronic hepatitis C virus infection"</a>.)</p><p>The optimal approach to treatment for patients with chronic HCV infection who are starting or receiving TNF-alpha inhibitor therapy has not been determined. We generally tailor our approach based on patient characteristics (eg, degree of liver injury, acuity of HCV infection, and need for the TNF-alpha inhibitor). In general, we prefer to start antiviral therapy and assess virologic response before starting anti-TNF inhibitor therapy. However, case reports suggest that concurrent treatment with TNF-alpha inhibitor and antiviral therapy may be safe for patients without liver injury [<a href="#rid53">53</a>]. One randomized trial of <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a> as adjunctive therapy to IFN-alpha plus <a class="drug drug_general" data-topicid="9860" href="/d/drug information/9860.html" rel="external">ribavirin</a> (a regimen no longer used) found that etanercept improved the virologic response rate and decreased the rate of adverse events [<a href="#rid54">54</a>]. Even in the absence of antiviral treatment, worsening of HCV infection in patients receiving etanercept or <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> appear to be uncommon [<a href="#rid55">55-63</a>]. The American College of Rheumatology suggests etanercept as the preferred TNF-alpha inhibitor if such therapy is used in patients with HCV infection [<a href="#rid64">64</a>]. We agree with this approach.</p><p>By contrast, we avoid TNF-alpha inhibitors in patients with acute HCV infection or with chronic HCV infection with significant liver injury, defined as Child-Pugh classes B or C (<a class="calc calc_professional" href="/d/html/15639.html" rel="external">calculator 1</a>), because progression of HCV has been observed in some patients receiving a TNF-alpha inhibitor [<a href="#rid13">13,64</a>]. (See <a class="local">'Contraindications'</a> above.)</p><p class="headingAnchor" id="H12"><span class="h2">Herpes zoster</span><span class="headingEndMark"> — </span>There is an increased risk of herpes zoster in patients with underlying autoimmune diseases (eg, rheumatoid arthritis, inflammatory bowel disease), particularly in those receiving immunosuppressive therapies including glucocorticoids and disease-modifying antirheumatic drugs (DMARDs). (See  <a class="medical medical_review" href="/d/html/8327.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of herpes zoster", section on 'Autoimmune disease'</a>.)</p><p>There are conflicting data regarding the question of whether TNF-alpha inhibitors confer a greater risk of herpes zoster compared with nonbiologic therapies for autoimmune diseases. Several large population-based studies have been conducted, with those in the United States not finding an increased risk with TNF-alpha inhibitors, but those in Europe generally showing an increased risk. The largest study to address this issue was a multicenter cohort study performed in the United States that compared the incidence of herpes zoster in 33,324 patients initiating a TNF-alpha inhibitor and 25,742 patients initiating nonbiologic DMARDs (eg, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="10097" href="/d/drug information/10097.html" rel="external">leflunomide</a>); underlying diseases included rheumatoid arthritis, inflammatory bowel disease, psoriasis, psoriatic arthritis, and ankylosing spondylitis [<a href="#rid65">65</a>]. Patients who initiated a TNF-alpha inhibitor were not at higher risk for herpes zoster than patients initiating nonbiologic DMARDs, and no differences in risk were observed among <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a>, and <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a>. A large retrospective study of patients with rheumatoid arthritis among United States veterans also showed that TNF-alpha inhibitors increased the risk of herpes zoster to a similar degree as other nonbiologic therapies [<a href="#rid66">66</a>].</p><p>In contrast, in a prospective cohort study that included 5040 patients with rheumatoid arthritis in Europe, after adjustment for age, disease severity, and <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> use, use of <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> or <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a> was associated with a moderately increased risk of herpes zoster (hazard ratio [HR] 1.82, 95% CI 1.05-3.15) compared with nonbiologic DMARDs [<a href="#rid67">67</a>]. There was a trend toward an increased risk with <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a>, although it did not achieve statistical significance. A later analysis from the British Biologic Registry identified a significantly increased risk (HR between 1.5 [95% CI 1.1-2.0] and 2.2 [95% CI 1.4-3.4]) for the three TNF-alpha inhibitors evaluated (etanercept, infliximab, and adalimumab) [<a href="#rid68">68</a>]. It is unclear why European studies have found increased risk but United States studies have not. Differential use of prednisone (a strong risk factor for disease identified in all of the above studies) between European and United States studies might help explain the difference in findings.</p><p>The risk of herpes zoster has also been compared in those receiving a TNF-alpha inhibitor or another biologic DMARD. A cohort analysis of the Medicare population compared the risk of herpes zoster associated with TNF-alpha inhibitor therapy with other biologic DMARDs (eg, <a class="drug drug_general" data-topicid="8526" href="/d/drug information/8526.html" rel="external">abatacept</a>, <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a>, <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>) and suggested that the risk was similar between TNF-alpha inhibitors and other biologic DMARDs used to treat rheumatoid arthritis [<a href="#rid69">69</a>].</p><p class="headingAnchor" id="H13"><span class="h2">Human immunodeficiency virus</span><span class="headingEndMark"> — </span>There are several case reports describing the use of TNF-alpha inhibitors to treat rheumatoid arthritis or other inflammatory conditions in the setting of HIV infection [<a href="#rid70">70,71</a>]. In general, these reports suggest that TNF-alpha inhibition can be tolerated well by HIV-infected patients, provided that the patient is on an effective antiretroviral regimen before starting a TNF-alpha inhibitor.</p><p class="headingAnchor" id="H14"><span class="h2">Other viruses</span><span class="headingEndMark"> — </span>A number of other viral infections, such as those caused by cytomegalovirus, herpes simplex virus [<a href="#rid72">72</a>], and molluscum contagiosum, have been reported to occur in patients treated with TNF-alpha inhibitors, but the true nature of the association between these infections and TNF-alpha inhibition is not clear.</p><p class="headingAnchor" id="H15"><span class="h1">FUNGAL INFECTIONS</span><span class="headingEndMark"> — </span>The critical role of TNF-alpha in granuloma formation and its other contributions to host defense make granulomatous infections an anticipated complication of TNF-alpha inhibitors. Data from human studies have confirmed the heightened risk of granulomatous infections, including fungal infections, associated with TNF-alpha inhibitor use. (See  <a class="medical medical_review" href="/d/html/7970.html" rel="external">"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects", section on 'TNF-alpha and host defenses'</a>.)</p><p>In addition to fungal infections usually associated with granulomatous inflammation, cases of <em>Pneumocystis</em> pneumonia (PCP) have also been reported among patients treated with targeted TNF-alpha inhibition [<a href="#rid73">73,74</a>].</p><p class="headingAnchor" id="H16"><span class="h2">Granulomatous infections</span><span class="headingEndMark"> — </span>Fungi such as <em>H. capsulatum</em> and <em>Coccidioides </em>spp<em> </em>are found readily in the environment in endemic areas. Both reactivation of latent disease and new infections with histoplasmosis and coccidioidomycosis have been described with the use of TNF-alpha inhibitors, particularly <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> [<a href="#rid75">75</a>]. Blastomycosis is described less frequently as a complication of TNF-alpha inhibitor therapy. (See  <a class="medical medical_review" href="/d/html/2461.html" rel="external">"Diagnosis and treatment of disseminated histoplasmosis in patients without HIV"</a> and  <a class="medical medical_review" href="/d/html/2451.html" rel="external">"Diagnosis and treatment of pulmonary histoplasmosis"</a> and  <a class="medical medical_review" href="/d/html/2418.html" rel="external">"Management considerations, screening, and prevention of coccidioidomycosis in immunocompromised individuals and pregnant patients"</a> and  <a class="medical medical_review" href="/d/html/2458.html" rel="external">"Mycology, pathogenesis, and epidemiology of blastomycosis", section on 'Epidemiology'</a>.)</p><p>In 2008, the US Food and Drug Administration (FDA) issued a warning about the risk for pulmonary and disseminated histoplasmosis, coccidioidomycosis, blastomycosis, and other invasive fungal infections in patients undergoing treatment with <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> or other TNF-alpha inhibitors [<a href="#rid76">76</a>]. The warning is based on reports of 240 cases of histoplasmosis in patients treated with TNF-alpha inhibitors. In at least 21 of these reports, histoplasmosis was not recognized initially, which led to a delay in antifungal therapy; there were 12 fatal outcomes.</p><p>Clinicians should have a high index of suspicion for invasive fungal infections, particularly in patients who live in or have traveled to endemic regions, and investigate for these infections and treat promptly. Typical signs and symptoms of histoplasmosis and other invasive fungal infections include fever, malaise, weight loss, sweats, cough, dyspnea, pulmonary infiltrates on radiograph, or serious systemic illness including shock. (See  <a class="medical medical_review" href="/d/html/2455.html" rel="external">"Pathogenesis and clinical manifestations of disseminated histoplasmosis"</a> and  <a class="medical medical_review" href="/d/html/2450.html" rel="external">"Pathogenesis and clinical features of pulmonary histoplasmosis"</a>.)</p><p class="headingAnchor" id="H17"><span class="h3">Histoplasmosis</span><span class="headingEndMark"> — </span><em>H. capsulatum</em> is acquired through inhalation of mycelial fragments and microconidia, typically from soil. (See  <a class="medical medical_review" href="/d/html/2455.html" rel="external">"Pathogenesis and clinical manifestations of disseminated histoplasmosis"</a> and  <a class="medical medical_review" href="/d/html/2450.html" rel="external">"Pathogenesis and clinical features of pulmonary histoplasmosis"</a>.)</p><p>Ten cases of <em>H. capsulatum</em> infections were reported to the FDA Adverse Events Reporting System (AERS) from the late 1990s through July 2001 [<a href="#rid77">77</a>]. By September 2008, 240 additional cases of histoplasmosis associated with TNF-alpha inhibitor were reported to AERS, and since then this has been a well-recognized complication of TNF-alpha inhibitor therapy [<a href="#rid76">76</a>]. It is likely that these numbers are underestimates as the infection is not typically reportable to public health agencies. The largest series to date of histoplasmosis cases occurring in patients receiving a TNF-alpha inhibitor included 98 patients [<a href="#rid78">78</a>]. These cases occurred within an endemic region in the Midwest of the United States, and many were also using <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (44 percent) or <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> (34 percent). TNF-alpha inhibitor therapy was initially discontinued in 95 of 98 patients (96.9 percent) and later resumed in 25 of 74 (33.8 percent) either during or after successful antifungal therapy (median time to resumption was 12 months after diagnosis). Overall, 3.2 percent of patients died and nine (9 percent) developed immune reconstitution inflammatory syndrome (IRIS) during therapy, of whom three were given steroids for IRIS management. No patients reinstituted TNF-antagonists for IRIS. (See  <a class="medical medical_review" href="/d/html/3762.html" rel="external">"Immune reconstitution inflammatory syndrome"</a>.)</p><p>Screening for histoplasmosis involves questioning TNF-alpha inhibitor candidates about potential exposures with specific reference to high-risk activities (eg, demolition of old buildings, cleaning chicken coops, spelunking) in endemic areas and symptoms of active or recent histoplasmosis [<a href="#rid79">79</a>]. Areas of endemicity include parts of the United States (particularly Midwestern and central states), Mexico, Central and South America, Africa, and Asia. In patients with a history of high-risk activities, symptoms of active histoplasmosis, or a history of histoplasmosis within the past two years, a chest radiograph should be obtained. The routine use of <em>Histoplasma</em> serologies or antigen testing is not recommended for screening, as these tests are insensitive in this setting; however, these tests are indicated as part of the diagnostic evaluation in patients suspected of having histoplasmosis. As current diagnostic tests perform poorly in immunocompromised hosts, an empiric antifungal therapy may be needed when there is a high suspicion of disease [<a href="#rid80">80</a>]. The diagnosis and treatment of histoplasmosis are discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/2450.html" rel="external">"Pathogenesis and clinical features of pulmonary histoplasmosis", section on 'Epidemiology'</a> and  <a class="medical medical_review" href="/d/html/2451.html" rel="external">"Diagnosis and treatment of pulmonary histoplasmosis"</a> and  <a class="medical medical_review" href="/d/html/2461.html" rel="external">"Diagnosis and treatment of disseminated histoplasmosis in patients without HIV"</a>.)</p><p>The FDA suggests that clinicians generally discontinue the TNF-alpha inhibitor in patients who develop histoplasmosis or other invasive fungal infections during therapy [<a href="#rid76">76</a>]. However, as discussed above, some patients have experienced a paradoxical clinical worsening following discontinuation of the TNF-alpha inhibitor despite evidence of improvement of the fungal infection; such a pattern is suggestive of IRIS [<a href="#rid79">79</a>]. In some cases, this has necessitated reinstitution of immunosuppressive therapy, typically with <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>. Similar reactions can occur during treatment of tuberculosis and other opportunistic infections. (See  <a class="medical medical_review" href="/d/html/3762.html" rel="external">"Immune reconstitution inflammatory syndrome"</a>.)</p><p class="headingAnchor" id="H18"><span class="h3">Coccidioidomycosis</span><span class="headingEndMark"> — </span><em>Coccidioides </em>spp are dimorphic fungi endemic to the southwestern United States and parts of Central and South America. (See  <a class="medical medical_review" href="/d/html/2460.html" rel="external">"Primary pulmonary coccidioidal infection"</a> and  <a class="medical medical_review" href="/d/html/2418.html" rel="external">"Management considerations, screening, and prevention of coccidioidomycosis in immunocompromised individuals and pregnant patients"</a>.)</p><p>There are limited data on the occurrence, prophylaxis, and management of <em>Coccidioides immitis</em> infections among patients treated with TNF-alpha inhibitors. In a study of patients from clinics in endemic areas in California, Arizona, and Nevada, the following findings were noted [<a href="#rid81">81</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Thirteen cases were reported over a five-year period; 12 were associated with <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>, and 1 was associated with <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a>. Two of the infections were believed to be reactivation of previous coccidioidal infections.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among the 247 patients treated with <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> and the 738 patients treated with other therapies for inflammatory arthritis, the rate of symptomatic coccidioidomycosis over the five-year observation period was significantly higher with infliximab (2.8 versus 0.5 percent, relative risk 5.2, 95% CI 1.5-17.7).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Eleven of the 12 patients receiving <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> were also receiving <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, and two were also taking additional immunosuppressive medications.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All 13 patients had pneumonia at presentation, and 4 had documented dissemination of the <em>Coccidioides</em> infection to the blood, spleen, peritoneum, or central nervous system.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two patients died (one from staphylococcal line sepsis during the course of therapy for coccidioidomycosis).</p><p></p><p>In a more recent case series report detailing 35 patients using anti-TNF therapy, most patients with pulmonary disease were able to successfully resume anti-TNF therapy during or after antifungal treatment [<a href="#rid82">82</a>].</p><p>In areas in which <em>Coccidioides</em> spp are endemic, recommendations prior to the institution of a TNF-alpha inhibitor include a chest radiograph and consideration of a coccidioidal serologic test for immunoglobulin (Ig)M and IgG. However, baseline testing may be of limited utility because, as shown in the prior study, most coccidioidomycosis cases after anti-TNF-alpha therapy represent acute infection rather than reactivation [<a href="#rid81">81</a>]. On the other hand, one retrospective study suggested that screening patients receiving a TNF-alpha inhibitor in an endemic area might reduce the risk of subsequent symptomatic coccidioidomycosis [<a href="#rid83">83</a>].</p><p>The possible role of antifungal prophylaxis to prevent coccidioidal infection is discussed separately. (See  <a class="medical medical_review" href="/d/html/2418.html" rel="external">"Management considerations, screening, and prevention of coccidioidomycosis in immunocompromised individuals and pregnant patients", section on 'Patients taking immunomodulatory agents'</a>.)</p><p class="headingAnchor" id="H19"><span class="h3">Cryptococcus</span><span class="headingEndMark"> — </span><em>C. neoformans</em> is an encapsulated fungus that is distributed worldwide. The organism is typically found in soil and in especially high concentrations near bird roosts. Inhalation of the organism frequently occurs after disruption of soil. (See  <a class="medical medical_review" href="/d/html/2448.html" rel="external">"Microbiology and epidemiology of Cryptococcus neoformans infection"</a>.)</p><p>In animal models of <em>Cryptococcus</em> infection, TNF-alpha inhibition is associated with impaired recruitment of activated CD4+ T cells and Langerhans cells to the area of infection and with an increased risk of dissemination [<a href="#rid4">4,84</a>].</p><p>Cryptococcal infections were described in 19 patients reported to AERS between 1998 and 2002 [<a href="#rid30">30</a>]. Eleven of the patients had received <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a>, and eight had received <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a> (4.7 and 7.1 infections per 100,000 treated patients, respectively, a difference that was not significantly different). Most patients in this report and others were receiving additional immunosuppressive agents, particularly <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> [<a href="#rid85">85-87</a>].</p><p>Among patients with AIDS who have experienced cryptococcal infections, secondary prophylaxis is recommended until immune reconstitution occurs. There are no data about whether secondary prophylaxis is necessary or optimal in patients receiving a TNF-alpha inhibitor who develop cryptococcosis. (See  <a class="medical medical_review" href="/d/html/83651.html" rel="external">"Cryptococcus neoformans meningoencephalitis in persons with HIV: Treatment and prevention", section on 'Preventing symptomatic disease'</a>.)</p><p class="headingAnchor" id="H20"><span class="h3">Aspergillosis</span><span class="headingEndMark"> — </span><em>Aspergillus</em> species (eg, <em>A. fumigatus</em>) are ubiquitous environmental fungi capable of causing a wide variety of diseases in both healthy and immunocompromised hosts. (See  <a class="medical medical_review" href="/d/html/2454.html" rel="external">"Epidemiology and clinical manifestations of invasive aspergillosis"</a>.)</p><p>TNF-alpha inhibition may increase the risk of aspergillosis through the inhibition of neutrophil recruitment. Case reports and small cases series exist of <em>A. fumigatus</em> infections associated with TNF-alpha inhibition [<a href="#rid30">30,88</a>]. However, the interpretation of many cases is complicated by the simultaneous use of several immunosuppressive agents.</p><p>Aspergillosis was noted in 39 patients in the AERS report cited above: 29 with <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> and 10 with <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a> (12.4 versus 8.8 per 100,000 patients, a difference that was not significant) [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H21"><span class="h2">Pneumocystis pneumonia</span><span class="headingEndMark"> — </span>A review from AERS from 1998 to 2003 included 84 patients with PCP associated with <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> use [<a href="#rid73">73</a>]. The following findings were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>The mean time between the first <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> infusion and the onset of PCP symptoms was 21 days.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Death occurred in 23 of the 84 patients (27 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Concomitant immunosuppressive medications included <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="9612" href="/d/drug information/9612.html" rel="external">6-mercaptopurine</a>, and <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">Prednisone</a> doses and CD4 lymphocyte counts at the time of PCP infection were not reported.</p><p></p><p>In a case-control study, risk factors for PCP in patients receiving <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> included older age, coexisting pulmonary disease, and high doses of glucocorticoids [<a href="#rid89">89</a>]. Because the risk of PCP correlates with high-dose glucocorticoid use in some studies, PCP prophylaxis should be considered among patients treated with TNF-alpha inhibitors if they are also receiving high-dose glucocorticoids (eg, ≥20 mg <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> equivalents daily for ≥4 weeks) or other intensive immunosuppression [<a href="#rid90">90</a>]. Otherwise, routine PCP prophylaxis for those using TNF therapy is likely of little benefit. (See  <a class="medical medical_review" href="/d/html/1393.html" rel="external">"Treatment and prevention of Pneumocystis pneumonia in patients without HIV", section on 'Prophylaxis'</a>.)</p><p>A later United States population-based study of nonviral opportunistic infections identified a significantly elevated crude incidence rate of 270 cases per 100,000 patient-years among those starting a TNF-alpha inhibitor compared with 170 cases per 100,000 for patients using nonbiologic disease-modifying antirheumatic drugs, and PCP was the most common opportunistic infection identified (crude incidence 56 cases per 100,000 patient-years) [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H22"><span class="h1">OTHER INFECTION ISSUES</span><span class="headingEndMark"> — </span>As noted by the preceding findings, there is clear evidence for an increased risk of a variety of infections among patients treated with TNF-alpha inhibitors. However, the risk of these infections must be interpreted in the context of the potential benefits and of the possible adverse effects of conventional therapies. The decision to use an anti-TNF-alpha agent is an individual one, based upon the specific clinical features and unique risk profile of a given patient.</p><p>Patients should be educated about the importance of recognizing symptoms and signs of infections, particularly fever, because of the heightened risk of these complications and the greater likelihood of disseminated infections among immunocompromised hosts. Patients with symptoms or signs of infections should be evaluated without delay.</p><p class="headingAnchor" id="H24"><span class="h2">Perioperative use of TNF-alpha inhibitors</span><span class="headingEndMark"> — </span>The use of TNF-alpha inhibitors has been associated with an increased risk of perioperative infections in some, but not all, studies. A meta-analysis that included eight observational studies and three case-control studies found an increased risk of surgical site infection for those receiving a TNF-alpha inhibitor at the time of surgery versus those without recent exposure (pooled odds ratio [OR] 2.47, 95% CI 1.66-3.68) [<a href="#rid91">91</a>]. The studies were small, however, and many had few infectious events. No randomized controlled trials were identified. Further, a real-world population-based analysis evaluated <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> in the perioperative setting and found no difference in postoperative infection in those stopping infliximab within four weeks of surgery compared with those stopping earlier [<a href="#rid92">92-94</a>]. Several other population-based studies found no difference in risk among those using TNF-alpha inhibitors just prior to surgery as compared with those using <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> and similar risks among patients using TNF-alpha inhibitors as compared with other biologics. </p><p>Although the data are mixed, based upon recommendations from the American College of Rheumatology and the American Association of Hip and Knee Surgeons, TNF-alpha inhibitors should generally be withheld for several weeks before orthopedic surgery (as close to one dosing cycle as scheduling allows) and can be resumed after evidence of wound healing, typically after 14 days [<a href="#rid95">95</a>]. However, the potential benefit of preventing some postoperative infections must be balanced against the risk of a perioperative flare in rheumatoid arthritis activity. If a TNF-alpha inhibitor is discontinued before a surgical procedure, close monitoring of the patient for a rheumatoid arthritis flare is necessary.</p><p class="headingAnchor" id="H25"><span class="h2">Combination therapy with anakinra</span><span class="headingEndMark"> — </span>A higher rate of serious infections has been observed in patients receiving the combination of <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a> and <a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">anakinra</a> (a recombinant human interleukin 1 receptor antagonist) compared with trials of either agent alone [<a href="#rid96">96</a>]. The use of TNF-alpha inhibitors in combination with anakinra is not recommended.</p><p class="headingAnchor" id="H2216772788"><span class="h1">VACCINES</span><span class="headingEndMark"> — </span>The approach to vaccination for patients receiving immunosuppressive therapy for autoimmune inflammatory rheumatic disorders is discussed separately. (See  <a class="medical medical_review" href="/d/html/103773.html" rel="external">"Immunizations in autoimmune inflammatory rheumatic disease in adults"</a>.)</p><p class="headingAnchor" id="H27"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessing the risk of serious infection – </strong>Tumor necrosis factor (TNF)-alpha inhibitor use is associated with an increased risk of serious infections. The increase in risk is seen with a variety of infections, including tuberculosis (TB) and bacterial, viral, and fungal infections. This risk must be interpreted in the context of the potential benefits and of the possible adverse effects of conventional therapies. (See <a class="local">'Assessing the risk of serious infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment screening for infections – </strong>Prior to initiating a TNF-alpha inhibitor, all patients should be screened for TB, hepatitis B, and hepatitis C. It is also important to obtain a history of possible exposure to endemic fungi. (See <a class="local">'Screening for infections'</a> above and  <a class="medical medical_review" href="/d/html/1411.html" rel="external">"Risk of mycobacterial infection associated with biologic agents and JAK inhibitors", section on 'Screening'</a> and <a class="local">'Granulomatous infections'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contraindications – </strong>TNF-alpha inhibitors should <strong>not</strong> be administered when any of the following infections are present (see <a class="local">'Contraindications'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Active bacterial infections or bacterial infections requiring antibiotic therapy</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Active TB or untreated latent TB (see  <a class="medical medical_review" href="/d/html/1411.html" rel="external">"Risk of mycobacterial infection associated with biologic agents and JAK inhibitors"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Active herpes zoster infection</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Active invasive fungal infections (eg, coccidioidomycosis, invasive aspergillosis)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nonhealed infected skin ulcers</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acute infection with hepatitis B virus (HBV) or hepatitis C virus (HCV), untreated chronic HBV infection, or chronic HBV or HCV infection with significant liver injury, defined as Child-Pugh classes B or C (<a class="calc calc_professional" href="/d/html/15639.html" rel="external">calculator 1</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bacterial infections – </strong>Because of the risk of listeriosis, patients on TNF-alpha inhibitors should follow recommendations to avoid foodborne infections. (See <a class="local">'Bacterial infections'</a> above and  <a class="medical medical_review" href="/d/html/1303.html" rel="external">"Treatment and prevention of Listeria monocytogenes infection", section on 'Prevention of foodborne infection'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Viral infections</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hepatitis B – </strong>In patients with untreated HBV infection, there is increased risk of HBV reactivation in the setting of TNF-alpha inhibitor therapy. In patients with untreated HBV infection who do not have Child-Pugh class B or C liver injury, a TNF-alpha inhibitor can be given, although some patients require antiviral therapy to prevent HBV reactivation:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For HBsAg-positive patients (ie, patients with chronic HBV) starting a TNF-alpha inhibitor, we recommend starting an antiviral agent prior to initiating the TNF-alpha inhibitor (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). We use tenofovir or <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">entecavir</a> when an antiviral agent is indicated.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In patients who are HBsAg negative but HBcAb positive (ie, patients with resolved HBV), we suggest monitoring for HBV reactivation rather than administering preventive antiviral therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). In such patients, we check HBV DNA and transaminase levels before starting therapy and every three months thereafter. We initiate antiviral therapy if reactivation occurs. (See <a class="local">'Hepatitis B'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hepatitis C</strong> – Patients with chronic HCV infection should be treated given the wide availability of safe and effective antiviral therapy. We generally individualize our approach based on patient characteristics (eg, degree of liver injury, acuity of HCV infection, and need for the TNF-alpha inhibitor). In general, we prefer to start antiviral therapy and assess virologic response before starting anti-TNF inhibitor therapy in patients with chronic infection. However, limited data suggest that concurrent treatment with TNF-alpha inhibitor and antiviral therapy may be safe for patients without liver injury. By contrast, we avoid TNF-alpha inhibitors in patients with acute HCV infection or with chronic HCV infection with significant liver injury, defined as Child-Pugh classes B or C. If TNF-alpha inhibitor therapy is used in patients with HCV infection, we suggest <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a> rather than another TNF-alpha inhibitor (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Hepatitis C'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Herpes zoster</strong> – There is an increased risk of herpes zoster in patients with underlying autoimmune diseases, particularly among those receiving immunosuppressive therapies including glucocorticoids. However, in United States studies (unlike those in Europe), the risk of herpes zoster in patients receiving a TNF-alpha inhibitor does not appear to be higher than in patients receiving nonbiologic disease-modifying antirheumatic drugs (eg, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="10097" href="/d/drug information/10097.html" rel="external">leflunomide</a>), and the risk appears similar to other biologics used in autoimmune disease [<a href="#rid97">97</a>]. (See <a class="local">'Herpes zoster'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Human immunodeficiency virus</strong> – TNF-alpha inhibition use in patients infected with HIV appears to be safe, provided that the patient is on an effective antiretroviral regimen before starting a TNF-alpha inhibitor. (See <a class="local">'Human immunodeficiency virus'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fungal infections</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Endemic fungi – </strong>Case series of histoplasmosis, coccidioidomycosis, cryptococcosis, and other invasive fungal infections indicate an increased risk through either new infections or reactivation of latent ones, although the former is likely much more common. Clinicians caring for patients in regions that are endemic for invasive fungal infections must maintain a high degree of suspicion for the occurrence of such complications. (See <a class="local">'Fungal infections'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pneumocystis pneumonia – </strong>Cases of <em>Pneumocystis</em> pneumonia (PCP) have been reported among patients treated with TNF-alpha inhibitors. Given the relatively low level of risk of PCP associated with TNF-alpha inhibitors, prophylaxis for patients receiving a TNF-alpha inhibitor is not recommended unless patients have other indications for prophylaxis (eg, receipt of high-dose glucocorticoids). (See  <a class="medical medical_review" href="/d/html/1393.html" rel="external">"Treatment and prevention of Pneumocystis pneumonia in patients without HIV", section on 'Prophylaxis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Perioperative use of TNF-alpha inhibitors – </strong>The use of TNF-alpha inhibitors has been associated with an increased risk of perioperative infections in some, but not all, studies. TNF-alpha inhibitors should generally be withheld for several weeks before orthopedic surgery (as close to one dosing cycle as scheduling allows) and can be resumed after evidence of wound healing, typically after 14 days. However, the potential benefit of preventing some postoperative infections must be balanced against the risk of a perioperative flare in rheumatoid arthritis activity. (See <a class="local">'Perioperative use of TNF-alpha inhibitors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combination therapy with </strong><a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">anakinra</a><strong> – </strong>The combination of a TNF-alpha inhibitor and anakinra (a recombinant human interleukin 1 receptor antagonist) is not recommended because of an increased risk of infection. (See <a class="local">'Combination therapy with anakinra'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccinations – </strong>Clinicians should ensure that patients are up to date on vaccinations before starting a course of TNF-alpha inhibition  (<a class="graphic graphic_figure graphicRef62130" href="/d/graphic/62130.html" rel="external">figure 1</a>). Live virus vaccines generally should <strong>not</strong> be administered to patients receiving therapy with a TNF-alpha inhibitor. Initiation of TNF-alpha inhibitor therapy should be delayed for at least four weeks after administration of a live-virus vaccine. (See  <a class="medical medical_review" href="/d/html/103773.html" rel="external">"Immunizations in autoimmune inflammatory rheumatic disease in adults"</a>.)</p><p></p><p class="headingAnchor" id="H592609949"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges John Stone, MD, MPH, and Kieren A Marr, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Koo S, Marty FM, Baden LR. Infectious complications associated with immunomodulating biologic agents. Infect Dis Clin North Am 2010; 24:285.</a></li><li><a class="nounderline abstract_t">Allendoerfer R, Deepe GS Jr. Blockade of endogenous TNF-alpha exacerbates primary and secondary pulmonary histoplasmosis by differential mechanisms. J Immunol 1998; 160:6072.</a></li><li><a class="nounderline abstract_t">Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995; 2:561.</a></li><li><a class="nounderline abstract_t">Huffnagle GB, Toews GB, Burdick MD, et al. Afferent phase production of TNF-alpha is required for the development of protective T cell immunity to Cryptococcus neoformans. J Immunol 1996; 157:4529.</a></li><li><a class="nounderline abstract_t">Marino MW, Dunn A, Grail D, et al. Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci U S A 1997; 94:8093.</a></li><li><a class="nounderline abstract_t">Mehrad B, Strieter RM, Standiford TJ. Role of TNF-alpha in pulmonary host defense in murine invasive aspergillosis. J Immunol 1999; 162:1633.</a></li><li><a class="nounderline abstract_t">Randhawa PS. Lymphocyte subsets in granulomas of human tuberculosis: an in situ immunofluorescence study using monoclonal antibodies. Pathology 1990; 22:153.</a></li><li><a class="nounderline abstract_t">Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3:148.</a></li><li><a class="nounderline abstract_t">Furst DE, Keystone EC, So AK, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis 2013; 72 Suppl 2:ii2.</a></li><li><a class="nounderline abstract_t">D'Haens GR, Panaccione R, Higgins PD, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011; 106:199.</a></li><li><a class="nounderline abstract_t">Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020; 79:685.</a></li><li><a class="nounderline abstract_t">Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken) 2016; 68:1.</a></li><li><a class="nounderline abstract_t">Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59:762.</a></li><li><a class="nounderline abstract_t">Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002; 46:2287.</a></li><li><a class="nounderline abstract_t">Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011; :CD008794.</a></li><li><a class="nounderline abstract_t">Singh JA, Cameron C, Noorbaloochi S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet 2015; 386:258.</a></li><li><a class="nounderline abstract_t">Winthrop KL. Infections and biologic therapy in rheumatoid arthritis: our changing understanding of risk and prevention. Rheum Dis Clin North Am 2012; 38:727.</a></li><li><a class="nounderline abstract_t">Yun H, Xie F, Delzell E, et al. Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy. Ann Rheum Dis 2015; 74:1065.</a></li><li><a class="nounderline abstract_t">Curtis JR, Yang S, Patkar NM, et al. Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2014; 66:990.</a></li><li><a class="nounderline abstract_t">Curtis JR, Xie F, Chen L, et al. Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2012; 64:1480.</a></li><li><a class="nounderline abstract_t">Rutherford AI, Subesinghe S, Hyrich KL, Galloway JB. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis 2018; 77:905.</a></li><li><a class="nounderline abstract_t">Strangfeld A, Eveslage M, Schneider M, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 2011; 70:1914.</a></li><li><a class="nounderline abstract_t">Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011; 306:2331.</a></li><li><a class="nounderline abstract_t">Dixon W, Felson DT. Is anti-TNF therapy safer than previously thought? JAMA 2011; 306:2380.</a></li><li class="breakAll">US Food and Drug Administration. FDA Drug Safety Communication: drug labels for the tumor necrosis factor-alpha (TNFα) blockers now include warnings about infection with Legionella and Listeria bacteria. http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm (Accessed on July 03, 2023).</li><li><a class="nounderline abstract_t">Galloway JB, Hyrich KL, Mercer LK, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2011; 50:124.</a></li><li><a class="nounderline abstract_t">Toussi SS, Pan N, Walters HM, Walsh TJ. Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-α inhibitors: systematic review of the literature. Clin Infect Dis 2013; 57:1318.</a></li><li><a class="nounderline abstract_t">Dixon WG, Symmons DP, Lunt M, et al. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007; 56:2896.</a></li><li><a class="nounderline abstract_t">Winthrop KL, Baxter R, Liu L, et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis 2013; 72:37.</a></li><li><a class="nounderline abstract_t">Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38:1261.</a></li><li><a class="nounderline abstract_t">Galloway JB, Hyrich KL, Mercer LK, et al. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011; 70:1810.</a></li><li><a class="nounderline abstract_t">Slifman NR, Gershon SK, Lee JH, et al. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 2003; 48:319.</a></li><li><a class="nounderline abstract_t">Nakane A, Minagawa T, Kato K. Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection. Infect Immun 1988; 56:2563.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Listeriosis. http://www.cdc.gov/listeria/ (Accessed on July 03, 2023).</li><li><a class="nounderline abstract_t">Lanternier F, Tubach F, Ravaud P, et al. Incidence and risk factors of Legionella pneumophila pneumonia during anti-tumor necrosis factor therapy: a prospective French study. Chest 2013; 144:990.</a></li><li><a class="nounderline abstract_t">Baddley JW, Winthrop KL, Chen L, et al. Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study. Ann Rheum Dis 2014; 73:1942.</a></li><li><a class="nounderline abstract_t">Guidotti LG, Ishikawa T, Hobbs MV, et al. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996; 4:25.</a></li><li><a class="nounderline abstract_t">Guidotti LG, Ando K, Hobbs MV, et al. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci U S A 1994; 91:3764.</a></li><li><a class="nounderline abstract_t">Nelson DR, Lim HL, Marousis CG, et al. Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection. Dig Dis Sci 1997; 42:2487.</a></li><li><a class="nounderline abstract_t">Ungaro RC, Brenner EJ, Gearry RB, et al. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut 2021; 70:725.</a></li><li><a class="nounderline abstract_t">Strangfeld A, Schäfer M, Gianfrancesco MA, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 2021; 80:930.</a></li><li><a class="nounderline abstract_t">Pasquetto V, Wieland SF, Uprichard SL, et al. Cytokine-sensitive replication of hepatitis B virus in immortalized mouse hepatocyte cultures. J Virol 2002; 76:5646.</a></li><li><a class="nounderline abstract_t">Wendling D, Auge B, Bettinger D, et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis 2005; 64:788.</a></li><li><a class="nounderline abstract_t">Ueno Y, Tanaka S, Shimamoto M, et al. Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B. Dig Dis Sci 2005; 50:163.</a></li><li><a class="nounderline abstract_t">Ostuni P, Botsios C, Punzi L, et al. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003; 62:686.</a></li><li><a class="nounderline abstract_t">Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease. J Rheumatol 2003; 30:1624.</a></li><li><a class="nounderline abstract_t">Esteve M, Saro C, González-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004; 53:1363.</a></li><li><a class="nounderline abstract_t">Vassilopoulos D, Calabrese LH. Viral hepatitis: review of arthritic complications and therapy for arthritis in the presence of active HBV/HCV. Curr Rheumatol Rep 2013; 15:319.</a></li><li><a class="nounderline abstract_t">Winthrop KL, Calabrese LH. Let the fog be lifted: screening for hepatitis B virus before biological therapy. Ann Rheum Dis 2011; 70:1701.</a></li><li><a class="nounderline abstract_t">Di Bisceglie AM, Lok AS, Martin P, et al. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology 2015; 61:703.</a></li><li><a class="nounderline abstract_t">Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken) 2021; 73:924.</a></li><li><a class="nounderline abstract_t">Barone M, Notarnicola A, Lopalco G, et al. Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection. Hepatology 2015; 62:40.</a></li><li><a class="nounderline abstract_t">Salvi M, Macaluso L, Luci C, et al. Safety and efficacy of anti-tumor necrosis factors α in patients with psoriasis and chronic hepatitis C. World J Clin Cases 2016; 4:49.</a></li><li><a class="nounderline abstract_t">Zein NN, Etanercept Study Group. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005; 42:315.</a></li><li><a class="nounderline abstract_t">del Valle García-Sánchez M, Gómez-Camacho F, Poyato-González A, et al. Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection. Inflamm Bowel Dis 2004; 10:701.</a></li><li><a class="nounderline abstract_t">Oniankitan O, Duvoux C, Challine D, et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 2004; 31:107.</a></li><li><a class="nounderline abstract_t">Magliocco MA, Gottlieb AB. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol 2004; 51:580.</a></li><li><a class="nounderline abstract_t">Parke FA, Reveille JD. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 2004; 51:800.</a></li><li><a class="nounderline abstract_t">Peterson JR, Hsu FC, Simkin PA, Wener MH. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003; 62:1078.</a></li><li><a class="nounderline abstract_t">Campbell S, Ghosh S. Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 2001; 13:191.</a></li><li><a class="nounderline abstract_t">Holtmann MH, Galle PR, Neurath MF. Treatment of patients with Crohn's disease and concomitant chronic hepatitis C with a chimeric monoclonal antibody to TNF. Am J Gastroenterol 2003; 98:504.</a></li><li><a class="nounderline abstract_t">Brunasso AM, Puntoni M, Gulia A, Massone C. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatology (Oxford) 2011; 50:1700.</a></li><li><a class="nounderline abstract_t">Pompili M, Biolato M, Miele L, Grieco A. Tumor necrosis factor-α inhibitors and chronic hepatitis C: a comprehensive literature review. World J Gastroenterol 2013; 19:7867.</a></li><li><a class="nounderline abstract_t">Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64:625.</a></li><li><a class="nounderline abstract_t">Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA 2013; 309:887.</a></li><li><a class="nounderline abstract_t">McDonald JR, Zeringue AL, Caplan L, et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis 2009; 48:1364.</a></li><li><a class="nounderline abstract_t">Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009; 301:737.</a></li><li><a class="nounderline abstract_t">Galloway JB, Mercer LK, Moseley A, et al. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2013; 72:229.</a></li><li><a class="nounderline abstract_t">Yun H, Xie F, Delzell E, et al. Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy. Arthritis Care Res (Hoboken) 2015; 67:731.</a></li><li><a class="nounderline abstract_t">Kaur PP, Chan VC, Berney SN. Successful etanercept use in an HIV-positive patient with rheumatoid arthritis. J Clin Rheumatol 2007; 13:79.</a></li><li><a class="nounderline abstract_t">Cepeda EJ, Williams FM, Ishimori ML, et al. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis 2008; 67:710.</a></li><li><a class="nounderline abstract_t">Bradford RD, Pettit AC, Wright PW, et al. Herpes simplex encephalitis during treatment with tumor necrosis factor-alpha inhibitors. Clin Infect Dis 2009; 49:924.</a></li><li><a class="nounderline abstract_t">Kaur N, Mahl TC. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci 2007; 52:1481.</a></li><li><a class="nounderline abstract_t">Seddik M, Meliez H, Seguy D, et al. Pneumocystis jiroveci (carinii) pneumonia following initiation of infliximab and azathioprine therapy in a patient with Crohn's disease. Inflamm Bowel Dis 2004; 10:436.</a></li><li><a class="nounderline abstract_t">Wallis RS, Broder M, Wong J, et al. Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis 2005; 41 Suppl 3:S194.</a></li><li class="breakAll">US Food and Drug Administration. Infliximab. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103772s5401lbl.pdf (Accessed on November 15, 2023).</li><li><a class="nounderline abstract_t">Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002; 46:2565.</a></li><li><a class="nounderline abstract_t">Vergidis P, Avery RK, Wheat LJ, et al. Histoplasmosis complicating tumor necrosis factor-α blocker therapy: a retrospective analysis of 98 cases. Clin Infect Dis 2015; 61:409.</a></li><li><a class="nounderline abstract_t">Hage CA, Bowyer S, Tarvin SE, et al. Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy. Clin Infect Dis 2010; 50:85.</a></li><li><a class="nounderline abstract_t">Hage CA, Ribes JA, Wengenack NL, et al. A multicenter evaluation of tests for diagnosis of histoplasmosis. Clin Infect Dis 2011; 53:448.</a></li><li><a class="nounderline abstract_t">Bergstrom L, Yocum DE, Ampel NM, et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum 2004; 50:1959.</a></li><li><a class="nounderline abstract_t">Taroumian S, Knowles SL, Lisse JR, et al. Management of coccidioidomycosis in patients receiving biologic response modifiers or disease-modifying antirheumatic drugs. Arthritis Care Res (Hoboken) 2012; 64:1903.</a></li><li><a class="nounderline abstract_t">Choi K, Deval N, Vyas A, et al. The Utility of Screening for Coccidioidomycosis in Recipients of Inhibitors of Tumor Necrosis Factor α. Clin Infect Dis 2019; 68:1024.</a></li><li><a class="nounderline abstract_t">Bauman SK, Huffnagle GB, Murphy JW. Effects of tumor necrosis factor alpha on dendritic cell accumulation in lymph nodes draining the immunization site and the impact on the anticryptococcal cell-mediated immune response. Infect Immun 2003; 71:68.</a></li><li><a class="nounderline abstract_t">True DG, Penmetcha M, Peckham SJ. Disseminated cryptococcal infection in rheumatoid arthritis treated with methotrexate and infliximab. J Rheumatol 2002; 29:1561.</a></li><li><a class="nounderline abstract_t">Shrestha RK, Stoller JK, Honari G, et al. Pneumonia due to Cryptococcus neoformans in a patient receiving infliximab: possible zoonotic transmission from a pet cockatiel. Respir Care 2004; 49:606.</a></li><li><a class="nounderline abstract_t">Hage CA, Wood KL, Winer-Muram HT, et al. Pulmonary cryptococcosis after initiation of anti-tumor necrosis factor-alpha therapy. Chest 2003; 124:2395.</a></li><li><a class="nounderline abstract_t">Warris A, Bjørneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001; 344:1099.</a></li><li><a class="nounderline abstract_t">Harigai M, Koike R, Miyasaka N, Pneumocystis Pneumonia under Anti-Tumor Necrosis Factor Therapy (PAT) Study Group. Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med 2007; 357:1874.</a></li><li><a class="nounderline abstract_t">Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 2004; 17:770.</a></li><li><a class="nounderline abstract_t">Goodman SM, Menon I, Christos PJ, et al. Management of perioperative tumour necrosis factor α inhibitors in rheumatoid arthritis patients undergoing arthroplasty: a systematic review and meta-analysis. Rheumatology (Oxford) 2016; 55:573.</a></li><li><a class="nounderline abstract_t">George MD, Baker JF, Winthrop K, et al. Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty: A Cohort Study. Ann Intern Med 2019; 170:825.</a></li><li><a class="nounderline abstract_t">George MD, Baker JF, Winthrop KL, et al. Immunosuppression and the risk of readmission and mortality in patients with rheumatoid arthritis undergoing hip fracture, abdominopelvic and cardiac surgery. Ann Rheum Dis 2020; 79:573.</a></li><li><a class="nounderline abstract_t">George MD, Baker JF, Hsu JY, et al. Perioperative Timing of Infliximab and the Risk of Serious Infection After Elective Hip and Knee Arthroplasty. Arthritis Care Res (Hoboken) 2017; 69:1845.</a></li><li><a class="nounderline abstract_t">Goodman SM, Springer B, Guyatt G, et al. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. Arthritis Care Res (Hoboken) 2017; 69:1111.</a></li><li><a class="nounderline abstract_t">Weisman MH. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. J Rheumatol Suppl 2002; 65:33.</a></li><li><a class="nounderline abstract_t">Curtis JR, Xie F, Yun H, et al. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis 2016; 75:1843.</a></li></ol></div><div id="topicVersionRevision">Topic 1410 Version 42.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20466271" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Infectious complications associated with immunomodulating biologic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9637524" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Blockade of endogenous TNF-alpha exacerbates primary and secondary pulmonary histoplasmosis by differential mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7540941" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8906831" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Afferent phase production of TNF-alpha is required for the development of protective T cell immunity to Cryptococcus neoformans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9223320" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Characterization of tumor necrosis factor-deficient mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9973423" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Role of TNF-alpha in pulmonary host defense in murine invasive aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2243727" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Lymphocyte subsets in granulomas of human tuberculosis: an in situ immunofluorescence study using monoclonal antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12614731" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23532441" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21045814" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31969328" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26545825" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18512708" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12355475" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21328309" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Adverse effects of biologics: a network meta-analysis and Cochrane overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25975452" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23137579" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Infections and biologic therapy in rheumatoid arthritis: our changing understanding of risk and prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24608404" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24470378" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22833479" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29592917" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21791449" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22056398" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Initiation of tumor necrosis factor-αantagonists and the risk of hospitalization for infection in patients with autoimmune diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22056396" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Is anti-TNF therapy safer than previously thought?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22056396" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Is anti-TNF therapy safer than previously thought?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20675706" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23899685" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-αinhibitors: systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17763441" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22523429" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Mycobacterial diseases and antitumour necrosis factor therapy in USA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15127338" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Granulomatous infectious diseases associated with tumor necrosis factor antagonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21784730" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12571839" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3138177" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3138177" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23744173" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Incidence and risk factors of Legionella pneumophila pneumonia during anti-tumor necrosis factor therapy: a prospective French study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23852763" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8574849" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8170985" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9440625" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33082265" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effect of IBD medications on COVID-19 outcomes: results from an international registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33504483" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11991993" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Cytokine-sensitive replication of hepatitis B virus in immortalized mouse hepatocyte cultures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15834064" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15712655" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12810441" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12858469" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15306601" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23436024" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Viral hepatitis: review of arthritic complications and therapy for arthritis in the presence of active HBV/HCV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21893581" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Let the fog be lifted: screening for hepatitis B virus before biological therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25412906" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34101387" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25613809" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26881191" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Safety and efficacy of anti-tumor necrosis factorsαin patients with psoriasis and chronic hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15791697" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15472541" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14705228" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15389194" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15478165" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14583571" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11246620" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12591081" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Treatment of patients with Crohn's disease and concomitant chronic hepatitis C with a chimeric monoclonal antibody to TNF.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21690185" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24307780" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Tumor necrosis factor-αinhibitors and chronic hepatitis C: a comprehensive literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22473917" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23462785" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19368499" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19224750" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22532633" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25201241" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17414534" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Successful etanercept use in an HIV-positive patient with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18079191" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19681709" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Herpes simplex encephalitis during treatment with tumor necrosis factor-alpha inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17429728" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15475754" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Pneumocystis jiroveci (carinii) pneumonia following initiation of infliximab and azathioprine therapy in a patient with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15983899" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Reactivation of latent granulomatous infections by infliximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15983899" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Reactivation of latent granulomatous infections by infliximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12384912" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25870331" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Histoplasmosis complicating tumor necrosis factor-αblocker therapy: a retrospective analysis of 98 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19951231" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21810734" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : A multicenter evaluation of tests for diagnosis of histoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15188373" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22745051" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Management of coccidioidomycosis in patients receiving biologic response modifiers or disease-modifying antirheumatic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30084971" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : The Utility of Screening for Coccidioidomycosis in Recipients of Inhibitors of Tumor Necrosis Factorα.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12496150" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Effects of tumor necrosis factor alpha on dendritic cell accumulation in lymph nodes draining the immunization site and the impact on the anticryptococcal cell-mediated immune response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12136922" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Disseminated cryptococcal infection in rheumatoid arthritis treated with methotrexate and infliximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15165294" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Pneumonia due to Cryptococcus neoformans in a patient receiving infliximab: possible zoonotic transmission from a pet cockatiel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14665529" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Pulmonary cryptococcosis after initiation of anti-tumor necrosis factor-alpha therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11291675" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Invasive pulmonary aspergillosis associated with infliximab therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17978303" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Pneumocystis pneumonia associated with infliximab in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15489347" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26447162" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Management of perioperative tumour necrosis factorαinhibitors in rheumatoid arthritis patients undergoing arthroplasty: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31108503" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty: A Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32209540" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Immunosuppression and the risk of readmission and mortality in patients with rheumatoid arthritis undergoing hip fracture, abdominopelvic and cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28129484" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Perioperative Timing of Infliximab and the Risk of Serious Infection After Elective Hip and Knee Arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28620917" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12236621" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : What are the risks of biologic therapy in rheumatoid arthritis? An update on safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27113415" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
